BioSpace News Archive

MorphoSys U.S. Inc. announced that the National Comprehensive Cancer Network Clinical Practice Guidelines ) in Oncology for B-cell Lymphomas have been updated, and the designation for Monjuvi in combination with lenalidomide is now a Preferred Regimen for second-line therapy in patients with Diffuse Large B-cell Lymphoma who are not candidates for transplant.

CS Genetics, a privately held genomics-technology company, announced the appointment of Jay Harger, PhD, as Senior Vice President of Operations.

Champions Oncology, Inc., a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced its financial results for its third quarter of fiscal 2022, ended January 31, 2022.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD).

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that on March 14, 2022, the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of 667,725 shares of Iovance’s common stock to nineteen new non-executive employees.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), today reported financial results for the full year ended December 31, 2021 and summarized recent business highlights.

Inozyme Pharma, Inc. reported financial results for the full year ended December 31, 2021, and provided recent business highlights.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of an additional booster dose adults 65 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.

Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that it granted.

Lonza has expanded its renowned human stem cell offerings to provide human cord blood CD34+ hematopoietic stem cells (CB-CD34+ HSCs) in large batch sizes, meeting a critical and rapidly expanding market need.